Skip to main content
NewslettersWatchlist

Fsd Pharma Inc Subordinate Voting Share(HUGE-CN)
CSE

Today's Change
Delayed Last Update
Day Low0.4200
Day High0.4600
Open:0.4600
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change
Select a category then submit the form to load news
Newsfile
FSD Pharma Inc. Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency
ACCESSWIRE
FSD Pharma Announces US ATM Offering
ACCESSWIRE
FSD Pharma Inc. Announces Closing of Private Placement
ACCESSWIRE
FSD Pharma Inc. and Celly Nutrition Corp. Announce Completion of Plan of Arrangement
ACCESSWIRE
Update Provided on GBB Drink Lab, Inc. Litigation and Safety Shot Previously known as Jupiter Wellness
ACCESSWIRE
FSD Pharma Inc. Obtains Final Order for Plan of Arrangement
ACCESSWIRE
Goldman Small Cap Research Publishes New Research Report on FSD Pharma, Inc.
ACCESSWIRE
FSD Pharma Inc. Securityholders Approve Plan of Arrangement with Celly Nutrition Corp.
ACCESSWIRE
FSD Pharma Announces Distribution Date for Distribution of Celly Shares Pursuant to Plan of Arrangement
ACCESSWIRE
FSD Pharma Files Supplement to Management Information Circular in Connection with Special Meeting to be Held on November 20, 2023
ACCESSWIRE
FSD Pharma Provides Update on Proposed Dividend Distribution for Shareholders of FSD Pharma to Receive Shares of Celly Nutrition on a One for One Basis
ACCESSWIRE
FSD Pharma Files Preliminary Base Shelf Prospectus to Replace Expired Base Shelf Prospectus
ACCESSWIRE
FSD Pharma Files Management Information Circular for Proposed Arrangement with Celly Nu
ACCESSWIRE
FSD Pharma and Celly Nu Enter Into Arrangement Agreement
ACCESSWIRE
FSD Pharma Wins $2.8 Million Dollar Award Plus Accruing Interest from Dr. Raza Bokhari; Set Aside Motion Brought by Bokhari, Now CEO of Medicus Pharma, Dismissed by the Ontario Superior Court of Justice
ACCESSWIRE
FSD Pharma announces Interim Results from First-in-Human Clinical Trial of Lucid-MS (Lucid-21-302) for Multiple Sclerosis; The Report Shows Compound to be Safe and Well Tolerated
ACCESSWIRE
FSD Pharma Announces Analyst Coverage Initiated by Singular Research
ACCESSWIRE
FSD Pharma Selected to Present its Phase 1 Data on Lucid-MS at MSMilan 2023 – 9th Joint ECTRIMS-ACTRIMS Meeting for October 11-13, 2023
ACCESSWIRE
FSD Pharma Signs Definitive Agreement to Launch UNBUZZD, a Revolutionary Rapid Alcohol Detoxification Drink
Newswire.ca
DR. RAZA BOKHARI, FORMER EXECUTIVE CHAIRMAN AND CEO OF FSD PHARMA, FILES TWO ADDITIONAL CLAIMS AGAINST THE COMPANY SEEKING RELIEF AND MONETARY DAMAGES EXCEEDING $30.2 MILLION
Business Wire
FSD Pharma to Present at Sidoti Virtual Investor Conference May 10-11
Business Wire
FSD Pharma Achieves Milestone in Completion of Dosing of Sentinel Subjects in First-in-Human Clinical Trial of Lucid-MS (Lucid-21-302) for Multiple Sclerosis
Business Wire
FSD Pharma Announces Plan to Spin-Out Subsidiary as Distribution to Shareholders; Shareholder Meeting Scheduled for June 29, 2023
Business Wire
FSD Pharma Announces Filing of Year-End 2022 Results
Business Wire
FSD Pharma Adds Former Celsius Holdings CEO Gerry David to Board of Advisors
Business Wire
FSD Pharma Announces Its Australian Entity Receives Approval to Proceed With Phase 1 Clinical Trial of Lucid-201, a Candidate for the Potential Treatment of Major Depressive Disorder
Business Wire
FSD Pharma (Symbol: HUGE) Renews Shareholder Intelligence Services to Investigate Possible Naked Short Selling and Appeals to The Regulators and Oversight Bodies to Look Into The Short Selling Activity Of Its Stock
Business Wire
Original “Shark” and Iconic Entrepreneur Kevin Harrington Joins FSD Pharma Advisory Board
Business Wire
FSD Pharma Presenting Two Scientific Posters on Preclinical Toxicology and Efficacy Data of Lucid-21-302 (Lucid-MS) at Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) 2023 Forum
Business Wire
FSD Pharma Regains Compliance with NASDAQ Continued Listing Requirements
Business Wire
FSD Pharma Launches A New Research and Development Program Targeting Unmet Medical Needs for Alcohol Misuse
Business Wire
FSD Pharma Receives Regulatory Clearance for Its Proposed Phase-1 Clinical Trial of Lucid-21-302 (Lucid-MS), First-in-Class Multiple Sclerosis Drug Candidate

Profile

FSD Pharma Inc is a biopharmaceutical company developing three clinical candidates with the potential to address neuropsychiatric, neurodegenerative, and inflammatory disorders. Along with its subsidiaries, the group is focused on pharmaceutical research and development of its compound, FSD201, an ultra-micronized PEA, for the treatment of inflammatory diseases; Lucid-Psych is used in the treatment of mental health disorders and Lucid-MS is used in the treatment of neurodegenerative disorders. The company operates in two segments: Biopharmaceutical and Strategic Investments.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2024.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

Copyright © 2024 Morningstar. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.